Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.
作者信息
Sakurai Toshiharu, Nishida Naoshi, Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Hepatobiliary Surg Nutr. 2020 Dec;9(6):777-779. doi: 10.21037/hbsn.2020.03.04.
Abstract
摘要
相似文献
1
Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.有前景的抗癌疗法：免疫检查点抑制剂与分子靶向药物联合使用
Hepatobiliary Surg Nutr. 2020 Dec;9(6):777-779. doi: 10.21037/hbsn.2020.03.04.
2
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.免疫检查点抑制剂治疗相关免疫相关不良事件的最佳管理：综述与更新。
Int J Clin Oncol. 2018 Jun;23(3):410-420. doi: 10.1007/s10147-018-1259-6. Epub 2018 Mar 7.
3
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.胰腺癌中免疫检查点抑制剂的联合全身治疗：克服对单药检查点阻断的耐药性
Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9.
4
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?免疫检查点抑制剂：子宫内膜癌患者的一个有前景的选择？
J Clin Med. 2020 Jun 3;9(6):1721. doi: 10.3390/jcm9061721.
5
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.抗癌靶向治疗和免疫检查点抑制剂引起的口腔黏膜变化
Support Care Cancer. 2017 May;25(5):1713-1739. doi: 10.1007/s00520-017-3629-4. Epub 2017 Feb 22.
6
Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.基于纳米颗粒的免疫原性细胞死亡诱导剂和免疫检查点抑制剂的联合癌症免疫疗法。
Int J Nanomedicine. 2021 Feb 22;16:1435-1456. doi: 10.2147/IJN.S285999. eCollection 2021.
7
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy.联合免疫检查点抑制剂和激酶抑制超分子疗法以增强抗癌疗效。
ACS Nano. 2016 Oct 25;10(10):9227-9242. doi: 10.1021/acsnano.6b01600. Epub 2016 Sep 29.
8
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer.检查点抑制在微卫星稳定型结直肠癌中的新作用
J Pers Med. 2019 Jan 16;9(1):5. doi: 10.3390/jpm9010005.
9
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.卵巢癌中微卫星不稳定性、免疫细胞浸润与免疫检查点分子表达的关系：未来的免疫治疗策略。
Int J Mol Sci. 2019 Oct 16;20(20):5129. doi: 10.3390/ijms20205129.
10
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.采用 ASCO 价值框架和 ESMO 临床获益量表比较免疫检查点抑制剂与非免疫检查点抑制剂抗癌药物临床试验中的长期生存获益。
JAMA Netw Open. 2019 Jul 3;2(7):e196803. doi: 10.1001/jamanetworkopen.2019.6803.
引用本文的文献
1
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.探索长链非编码 RNA 在癌症免疫治疗中的潜在作用：全面综述。
Front Immunol. 2024 Aug 27;15:1446937. doi: 10.3389/fimmu.2024.1446937. eCollection 2024.
2
The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.骨形态发生蛋白（BMPs）家族的预后意义和免疫特征：泛癌多组学分析。
Technol Health Care. 2024;32(6):4123-4175. doi: 10.3233/THC-232004.
3
The prognostic values and immune characteristics of polo-like kinases (PLKs) family: A pan-cancer multi-omics analysis.Polo样激酶（PLKs）家族的预后价值和免疫特征：一项泛癌多组学分析。
Heliyon. 2024 Mar 21;10(7):e28048. doi: 10.1016/j.heliyon.2024.e28048. eCollection 2024 Apr 15.
4
Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy.顺铂吉西他滨、替雷利珠单抗和乐伐替尼序贯全身治疗用于晚期肝内胆管癌转化治疗
Front Oncol. 2021 Aug 30;11:691380. doi: 10.3389/fonc.2021.691380. eCollection 2021.
本文引用的文献
1
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.通过Src 同源性 2 结构域包含磷酸酶 2 阻断的联合治疗克服索拉非尼的适应性耐药在肝细胞癌中的作用。
Hepatology. 2020 Jul;72(1):155-168. doi: 10.1002/hep.30989. Epub 2020 Mar 31.
2
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.肝细胞癌的免疫肿瘤学疗法：现状与正在进行的试验
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
3
Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.联合癌症免疫疗法与分子靶向药物/抗CTLA-4抗体治疗肝细胞癌
Liver Cancer. 2019 Feb;8(1):1-11. doi: 10.1159/000496277. Epub 2019 Jan 15.
4
Combination Cancer Immunotherapy in Hepatocellular Carcinoma.肝细胞癌的联合癌症免疫疗法
Liver Cancer. 2018 Mar;7(1):20-27. doi: 10.1159/000486487. Epub 2018 Jan 31.
5
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.甘菊环素在肿瘤微环境中诱导信号转导和转录激活因子3（STAT3）激活，并导致肝细胞癌对索拉非尼产生耐药性。
Cancer Sci. 2017 Oct;108(10):1996-2003. doi: 10.1111/cas.13341. Epub 2017 Sep 2.
6
SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.SHP2由HBx-NF-κB通路诱导，并在人类早期肝细胞癌发展过程中促进纤维化。
Oncotarget. 2017 Apr 18;8(16):27263-27276. doi: 10.18632/oncotarget.15930.
7
Sticking It to Cancer with Molecular Glue for SHP2.利用分子胶靶向SHP2对抗癌症
Cancer Cell. 2016 Aug 8;30(2):194-196. doi: 10.1016/j.ccell.2016.07.010.
8
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.去γ-羧基凝血酶原通过激活Raf/MEK/ERK和PI3K/Akt/mTOR信号通路拮抗索拉非尼对人肝细胞癌的作用。
Oncotarget. 2016 Jun 14;7(24):36767-36782. doi: 10.18632/oncotarget.9168.
9
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.MAP 激酶抑制与 PD-L1 检查点阻断联合促进 T 细胞和抗肿瘤活性。
Immunity. 2016 Mar 15;44(3):609-621. doi: 10.1016/j.immuni.2016.01.024. Epub 2016 Mar 2.
10
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.索拉非尼在人肝细胞癌中耐药的分子机制及预测
Dig Dis. 2015 Oct;33(6):771-9. doi: 10.1159/000439102. Epub 2015 Oct 21.
Zotero 插件